vs
Jerash Holdings (US), Inc.（JRSH）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Jerash Holdings (US), Inc.的季度营收约是REGENXBIO Inc.的1.4倍（$41.8M vs $30.3M），Jerash Holdings (US), Inc.净利率更高（2.8% vs -221.3%，领先224.1%），REGENXBIO Inc.同比增速更快（43.0% vs 18.0%），Jerash Holdings (US), Inc.自由现金流更多（$-3.9M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 39.1%）
Jerash Holdings (US), Inc. 是一家全球化服装制造商，为国际知名零售及服饰品牌生产高品质外套、运动服、休闲装及功能性服饰，核心市场覆盖北美、欧洲及亚太地区，在约旦及东南亚设有生产基地。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
JRSH vs RGNX — 直观对比
营收规模更大
JRSH
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出25.0%
18.0%
净利率更高
JRSH
高出224.1%
-221.3%
自由现金流更多
JRSH
多$48.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
39.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.8M | $30.3M |
| 净利润 | $1.2M | $-67.1M |
| 毛利率 | 16.9% | — |
| 营业利润率 | 4.7% | -190.0% |
| 净利率 | 2.8% | -221.3% |
| 营收同比 | 18.0% | 43.0% |
| 净利润同比 | 20261.5% | -31.2% |
| 每股收益（稀释后） | $0.09 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JRSHRGNX
| Q4 25 | $41.8M | $30.3M | ||
| Q3 25 | $42.0M | $29.7M | ||
| Q2 25 | $39.6M | $21.4M | ||
| Q1 25 | $29.3M | $89.0M | ||
| Q4 24 | $35.4M | $21.2M | ||
| Q3 24 | $40.2M | $24.2M | ||
| Q2 24 | $40.9M | $22.3M | ||
| Q1 24 | $21.6M | $15.6M |
净利润JRSHRGNX
| Q4 25 | $1.2M | $-67.1M | ||
| Q3 25 | $461.6K | $-61.9M | ||
| Q2 25 | $318.7K | $-70.9M | ||
| Q1 25 | $-152.6K | $6.1M | ||
| Q4 24 | $-5.8K | $-51.2M | ||
| Q3 24 | $655.3K | $-59.6M | ||
| Q2 24 | $-1.3M | $-53.0M | ||
| Q1 24 | $-3.1M | $-63.3M |
毛利率JRSHRGNX
| Q4 25 | 16.9% | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 17.9% | — | ||
| Q4 24 | 15.2% | 70.2% | ||
| Q3 24 | 17.5% | 48.8% | ||
| Q2 24 | 11.3% | 52.5% | ||
| Q1 24 | 7.0% | 72.6% |
营业利润率JRSHRGNX
| Q4 25 | 4.7% | -190.0% | ||
| Q3 25 | 2.6% | -176.3% | ||
| Q2 25 | 2.4% | -296.3% | ||
| Q1 25 | 1.5% | 13.6% | ||
| Q4 24 | 2.0% | -242.1% | ||
| Q3 24 | 2.8% | -256.6% | ||
| Q2 24 | -2.0% | -251.3% | ||
| Q1 24 | -14.0% | -408.8% |
净利率JRSHRGNX
| Q4 25 | 2.8% | -221.3% | ||
| Q3 25 | 1.1% | -208.3% | ||
| Q2 25 | 0.8% | -331.8% | ||
| Q1 25 | -0.5% | 6.8% | ||
| Q4 24 | -0.0% | -241.3% | ||
| Q3 24 | 1.6% | -246.3% | ||
| Q2 24 | -3.3% | -237.7% | ||
| Q1 24 | -14.3% | -405.4% |
每股收益（稀释后）JRSHRGNX
| Q4 25 | $0.09 | $-1.30 | ||
| Q3 25 | $0.04 | $-1.20 | ||
| Q2 25 | $0.03 | $-1.38 | ||
| Q1 25 | $-0.01 | $0.12 | ||
| Q4 24 | $0.00 | $-0.99 | ||
| Q3 24 | $0.05 | $-1.17 | ||
| Q2 24 | $-0.11 | $-1.05 | ||
| Q1 24 | $-0.25 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $63.6M | $102.7M |
| 总资产 | $84.2M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资JRSHRGNX
| Q4 25 | $11.5M | $230.1M | ||
| Q3 25 | $12.0M | $274.2M | ||
| Q2 25 | $5.8M | $323.3M | ||
| Q1 25 | $13.3M | $267.9M | ||
| Q4 24 | $13.2M | $234.7M | ||
| Q3 24 | $16.3M | $255.5M | ||
| Q2 24 | $11.4M | $290.4M | ||
| Q1 24 | $12.4M | $338.7M |
股东权益JRSHRGNX
| Q4 25 | $63.6M | $102.7M | ||
| Q3 25 | $62.8M | $161.5M | ||
| Q2 25 | $62.7M | $213.7M | ||
| Q1 25 | $62.8M | $274.2M | ||
| Q4 24 | $63.1M | $259.7M | ||
| Q3 24 | $63.4M | $301.4M | ||
| Q2 24 | $62.9M | $348.3M | ||
| Q1 24 | $64.4M | $390.7M |
总资产JRSHRGNX
| Q4 25 | $84.2M | $453.0M | ||
| Q3 25 | $83.3M | $525.2M | ||
| Q2 25 | $81.7M | $581.0M | ||
| Q1 25 | $83.0M | $490.9M | ||
| Q4 24 | $79.8M | $466.0M | ||
| Q3 24 | $80.3M | $519.1M | ||
| Q2 24 | $76.7M | $569.4M | ||
| Q1 24 | $80.2M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-3.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | -9.3% | -174.0% |
| 资本支出强度资本支出/营收 | 0.2% | 1.7% |
| 现金转化率经营现金流/净利润 | -3.25× | — |
| 过去12个月自由现金流最近4个季度 | $-2.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流JRSHRGNX
| Q4 25 | $-3.8M | $-52.3M | ||
| Q3 25 | $6.8M | $-56.0M | ||
| Q2 25 | $-6.5M | $-49.3M | ||
| Q1 25 | $1.9M | $33.6M | ||
| Q4 24 | $-3.0M | $-31.6M | ||
| Q3 24 | $4.6M | $-40.5M | ||
| Q2 24 | $-2.2M | $-45.5M | ||
| Q1 24 | $-5.4M | $-55.5M |
自由现金流JRSHRGNX
| Q4 25 | $-3.9M | $-52.8M | ||
| Q3 25 | $6.4M | $-56.5M | ||
| Q2 25 | $-6.9M | $-49.7M | ||
| Q1 25 | $1.5M | $32.6M | ||
| Q4 24 | $-3.2M | $-32.7M | ||
| Q3 24 | $4.4M | $-40.9M | ||
| Q2 24 | $-2.3M | $-46.0M | ||
| Q1 24 | $-5.8M | $-56.0M |
自由现金流率JRSHRGNX
| Q4 25 | -9.3% | -174.0% | ||
| Q3 25 | 15.3% | -189.9% | ||
| Q2 25 | -17.5% | -232.8% | ||
| Q1 25 | 5.1% | 36.6% | ||
| Q4 24 | -8.9% | -154.2% | ||
| Q3 24 | 11.0% | -168.9% | ||
| Q2 24 | -5.7% | -206.2% | ||
| Q1 24 | -26.9% | -358.5% |
资本支出强度JRSHRGNX
| Q4 25 | 0.2% | 1.7% | ||
| Q3 25 | 0.9% | 1.7% | ||
| Q2 25 | 1.2% | 1.8% | ||
| Q1 25 | 1.6% | 1.2% | ||
| Q4 24 | 0.4% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 1.9% | 3.6% |
现金转化率JRSHRGNX
| Q4 25 | -3.25× | — | ||
| Q3 25 | 14.72× | — | ||
| Q2 25 | -20.33× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.06× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JRSH
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
